Sign In
Buy EYPT
$12.34
-0.190 (-1.52%)
At Close: Jun 03, 2026
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts
02:51am, Friday, 13'th Mar 2026
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
05:12pm, Wednesday, 04'th Mar 2026
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
09:20am, Wednesday, 04'th Mar 2026
EyePoint (EYPT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.64 per share a year ago.
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 04'th Mar 2026
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – –
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
07:00am, Wednesday, 25'th Feb 2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
09:02am, Wednesday, 18'th Feb 2026
EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
EyePoint Appoints Michael Campbell as Chief Commercial Officer
07:00am, Wednesday, 18'th Feb 2026
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversig
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Tuesday, 17'th Feb 2026
WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
09:40am, Monday, 16'th Feb 2026
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
07:00am, Thursday, 05'th Feb 2026
WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Friday, 16'th Jan 2026
WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:26pm, Tuesday, 13'th Jan 2026
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
07:00am, Wednesday, 07'th Jan 2026
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in
